Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of TECOS, which confirmed that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes; from ESC Congress 2015.

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of IMPROVE-IT that showed the cardiovascular benefits of ezetimibe are restricted to patients with type 2 diabetes; from ESC Congress 2015.